CD8A and lymphoma: In addition, considering for example that the proximity of CD8+ T cell–rich and immune-poor RCNs are associated with favorable survival, we anticipate that certain immunologic therapies, such as bispecific antibodies, show better efficacy in those patients in whose lymphomas T-cell and tumor cell compartments are located close to each other.